

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10602330
Filing Date	2003-06-23
First Named Inventor	Clarence Ahlem
Art Unit	1617
Examiner Name	Barbara Badio
Attorney Docket Number	202.2D2

U.S. PATENTS							Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	
	1						

If you wish to add additional U.S. Patent citation information please click the Add button.

U.S. PATENT APPLICATION PUBLICATIONS							Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	
	1						

FOREIGN PATENT DOCUMENTS							Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² i	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	Ts
	1							

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS							Remove
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.					Ts

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10602330
Filing Date	2003-06-23
First Named Inventor	Clarence Ahlem
Art Unit	1617
Examiner Name	Barbara Badio
Attorney Docket Number	202.202

1	A.L. Copley et al., On physiological microthromboembolization as the primary platelet function: elimination of invaded particles from the circulation and its pathogenic significance, <i>Thromb. Res.</i> , 8(3):251-262, 1976	<input type="checkbox"/>
2	J.G. Hirsch, Comparative bactericidal activities of blood serum and plasma serum, <i>J. Exp. Med.</i> , 112:15-22, 1960	<input type="checkbox"/>
3	J.E. Layton et al., Evidence for a novel <i>in vivo</i> control mechanism of granulopoiesis: mature cell-related control of a regulatory growth factor, <i>Blood</i> , 74(4):1303-1307, 1989 <i>Aging and innate immune cells</i>	<input type="checkbox"/>
4	T.P. Plackett et al., <i>Aging and innate immune cells</i> , <i>J. Leukocyte Biol.</i> , 76:291-299, 2004	<input type="checkbox"/>
5	J.J. Ramsey et al., Dietary restriction and aging in rhesus monkeys: the University of Wisconsin study, <i>Experimental Gerontol.</i> 35:1131-1149, 2000	<input type="checkbox"/>
6	J.F. Seymour et al., Mice lacking both granulocyte colony-stimulating factor (CSF) and granulocyte-macrophage CSF have impaired reproductive capacity, perturbed neonatal granulopoiesis, lung disease, amyloidosis, and reduced long-term survival, <i>Blood</i> , 90(8):3037-3049, 1997	<input type="checkbox"/>
7	D.R. Stickney et al., 5-Androstanediol improves survival in clinically unsupported rhesus monkeys with radiation-induced myelosuppression, <i>International Immunopharmacology</i> , 7:—, 2007, <i>in press</i>	<input type="checkbox"/>
8	A. W. Wognum et al., Differential expression of receptors for interleukin-3 on subsets of CD34-expressing hematopoietic cells of rhesus monkeys, <i>Blood</i> , 86(2):581-591, 1995	<input type="checkbox"/>
9	F.S.F. Kaya-Aerts et al., HE2100 (5-Androstan-3 β ,17 β -diol) after cytoreductive total body irradiation of rhesus monkeys promotes the recovery of immature CD34+ bone marrow cells, accelerates platelet, granulocyte and red cell reconstitution, and alleviates neutropenia and anemia, <i>Blood (ASH Annual Meeting Abstracts)</i> 106: abstract 4203, 2005	<input type="checkbox"/>
10	Goans, et al., Early dose assessment following severe radiation accidents, <i>Health Physics</i> , 72(4), pps.513-8, 1997	<input type="checkbox"/>
11	MacIntyre, A., et al., Weapons of mass destruction events with contaminated casualties, <i>MAMA</i> , 283(2) pps. 242-9, 2000	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10602330	
Filing Date	2003-06-23	
First Named Inventor	Clarence Ahlem	
Art Unit	1617	
Examiner Name	Barbara Radio	
Attorney Docket Number	202.202	

12	Singh, V, et al., Effects of whole-body gamma irradiation and 5-androstanediol administration on serum G-CSF, Immunopharmacology and Immunotoxicology, 27, pps 521-34, 2005	<input type="checkbox"/>
13	Whitnall, M., et al., Molecular specificity of 5-androstanediol as a systemic radioprotectant in mice, Immunopharmacology and Immunotoxicology, 27, pps 15-32, 2005	<input type="checkbox"/>
14	Diagnosis and Treatment of Radiation Injuries, Safety Reports series No. 2 (1998), Vienna: International Atomic Energy Agency, pp. 13	<input type="checkbox"/>
15	Stickney, D. et al., 5-androstanediol stimulates multilineage hematopoiesis in rhesus monkeys with radiation-induced myelosuppression, Int'l Immunopharmacology, 6, pp. 1706-13, 2006	<input type="checkbox"/>
16	MacVittie, T., et al, Combination therapy for radiation-induced bone marrow aplasia in nonhuman primates using synthokine SC-55494 and recombinant human granulocyte colony-stimulating factor, Blood, 887(10), pps 4129-35, 1996	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10602330
Filing Date	2003-06-23
First Named Inventor	Clarence Ahlem
Art Unit	1617
Examiner Name	Barbara Badio
Attorney Docket Number	202.202

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

See attached certification statement.

Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/ Daryl D. Muenchau /	Date (YYYY-MM-DD)	2007-02-21
Name/Print	Daryl D Muenchau	Registration Number	36616

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 216(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.